In related news, James Z. Huang has relocated to the east coast for personal reasons and will transition to a consulting role from his position as president. Mr. Huang, who joined Anesiva in September 2002 as vice president, business development & commercial operations, will remain very involved in the company's commercialization efforts.
During the meeting, Anesiva will review many parallel activities currently underway to prepare the market for Zingo, including:
-- Outreach to target hospitals to create "Zingo advocates" on the
medical and nursing staff who will support formulary acceptance.
-- Design and impending launch of http://www.manageivpain.com, a website
that targets nurses with the goal of encouraging them to focus on the
management of IV pain.
-- Creation and promotion of RNvoice -- an organization of influential
nurses with a passion for reducing pediatric needlestick pain.
-- Creation of educational and selling tools for use by sales teams.
-- Maximizing public relations initiatives through multiple channels to
raise awareness of Zingo.
The company will re-affirm its prior guidance that Zingo will likely be priced in the range of $12 - $16 per unit.
Fosun Joint Venture To Facilitate Automated Manufacturing, Increased Capacity and Cost of Goods Improvements
Anesiva will also provide information about its joint venture with
Wanbang Biopharma, a Fosun company, of XuZhou, China to establish
additional manufacturing capacity for worldwide supply. The additional
capacity will supplement the capacity provided by automated manufacturing
operations currently being qualified in the US. The C
|SOURCE Anesiva, Inc.|
Copyright©2007 PR Newswire.
All rights reserved